While regulated industry supported FDA guidance regarding responding to misinformation, they were concerned the draft guidance released in July was too narrow and brought up First Amendment concerns. The FDA received a dozen comments before the comment period ended Sept. 9. The comments were supportive of the FDA providing manufacturers with an avenue to combat misinformation... Read More